Research: FDA and EFSA Enforcement Actions Against Adaptogen Brands

FDA and EFSA Enforcement Actions Against Adaptogen Brands

The commercial proliferation of functional beverages infused with adaptogens, nootropics, and botanicals has drawn significant regulatory scrutiny across global markets. In the United States, the fda and the ftc closely monitor product claims and ingredient safety, while in the European Union, the european-food-safety-authority-efsa and the european-commission-ec enforce stringent pre-market authorization rules. Recent enforcement actions target unsubstantiated health claims, unapproved new drugs, and safety risks associated with novel botanical ingredients.

US Regulatory Framework and Enforcement

In the United States, functional-beverage-regulations mandate that dietary supplements and food products maintain a clear distinction between permissible structure-function-vs-drug-claims [2]. The fda governs product labeling and safety, requiring ingredients to either have a New Dietary Ingredient (NDI) notification or be gras-generally-recognized-as-safe [2]. Concurrently, the ftc regulates marketing and advertising, demanding “competent and reliable scientific evidence” to back up health claims [2, 11].

Joint Warning Letters and Efficacy Claims

The fda and ftc frequently issue joint warning letters to companies whose advertising steps into the realm of unapproved medical claims. Key enforcement targets include:

• COVID-19 and Severe Illness Claims: The agencies have issued warnings to companies (e.g., Benjaminmcevoy.com) claiming their adaptogen products could mitigate or cure COVID-19. Such claims classify the products as unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act) [1]. Similar joint letters were sent to Pure Nootropics, Gold Crown Natural Products, and TEK Naturals for claiming their supplements could treat Alzheimer’s, Parkinson’s, heart disease, and cancer [11].
• Mental Health Claims: In 2021, the fda issued warning letters to 10 companies illegally selling supplements that claimed to treat, mitigate, or prevent depression and other mental health disorders. The agency emphasized that consumers relying on these unapproved items might delay seeking legitimate, safe medical therapies [5].

The Clinical Substantiation Gap

A major trigger for enforcement is the clinical-substantiation-gap. Under FTC law, advertisers cannot claim a product improves cognitive function without well-controlled human clinical studies [11]. For example, the ftc filed a complaint against i-Health, Inc. and Martek Biosciences over their “BrainStrong Adult” supplement, culminating in a final order barring them from claiming the product prevents cognitive decline or improves memory without truthful, clinical support [14].

Additionally, pure cognitive enhancement supplements (like the piracetam analogs sold by Pure Nootropics) have faced class-action lawsuits following FDA warnings, as clinical studies indicate these supplements pose serious health risks, including unpredictable dosing, blood pressure fluctuations, and dependence [12].

CBD and Unsafe Food Additives

The fda has aggressively targeted food and beverage brands incorporating cannabidiol (CBD). In November 2022, warning letters were issued to five companies for selling CBD-infused food and beverage products, classifying them as adulterated due to the presence of an “unsafe food additive” [3, 4]. The fda highlighted specific safety concerns, including the potential for CBD to interact negatively with other ingredients (such as altering caffeine metabolism) and the risks of accidental overconsumption from dosage formats that appeal to children, like gummies and cookies [3, 4].

EU Regulatory Framework and Enforcement

In the European Union, the regulatory environment for functional beverages is highly restrictive, governed primarily by novel-food-regulations [6, 7].

Novel Food Authorizations

Any food or botanical ingredient that was not significantly consumed in the EU before May 15, 1997, is classified as a “novel food” [6, 8, 10]. The european-food-safety-authority-efsa requires a rigorous safety assessment before these ingredients can be marketed. Applications must include extensive toxicological, absorption, distribution, metabolism, and excretion (ADME) data [6]. If an adaptogen or botanical extract lacks this pre-market authorization, it is illegal to sell within the EU [8].

Strict Control on Health Claims

The EU has seen a tangible increase in enforcement against unsubstantiated marketing hype. Any new health claims must undergo prior approval through a dossier submission to the european-food-safety-authority-efsa [7]. Furthermore, functional beverages must adhere to maximum and minimum limits for vitamins, minerals, and active ingredients to avoid adverse gastrointestinal or physiological effects [7]. For instance, while EFSA establishes acceptable daily intakes for functional additives like Fructooligosaccharides (FOS), the recommended limit in functional beverages is generally capped at 5 grams per serving to prevent side effects [9].

UK Context and Advertising Standards

In the UK, regulatory bodies closely align with strict European principles regarding functional ingredients. The advertising-standards-authority-asa heavily polices nootropic beverage claims. Phrases like “treats brain fog” or “cures memory problems” are explicitly prohibited and violate advertising standards [13]. If a brand claims a beverage treats a medical condition, the Medicines and Healthcare products Regulatory Agency (MHRA) requires the product to hold a medicinal license [13].

Contradictions and Gaps in the Regulatory Landscape

• FTC vs. FDA Standards: A significant regulatory nuance exists between the fda and the ftc. The Dietary Supplement Health and Education Act (DSHEA) allows certain “structure/function” claims on labels without pre-approval. However, the ftc evaluates advertising using its own standard. A claim that technically bypasses FDA scrutiny as a structure/function claim may still be deemed deceptive by the ftc if it lacks “competent and reliable scientific evidence” [15].
• beverage-vs-supplement-ambiguity: Brands often exploit the blurred lines between conventional foods, beverages, and dietary supplements. Regulators face challenges enforcing rules when a product is packaged like a beverage (governed by standard food additive rules) but marketed with supplement-style therapeutic claims [2, 13].
• Global Fragmentation: While the US operates on a reactive model (allowing many botanicals to market unless proven unsafe or making drug claims), the EU operates on a strict proactive model (novel-food-regulations), making it exceedingly difficult for global adaptogen brands to use identical formulations across continents [6, 8]. Regulators like India’s food-safety-and-standards-authority-of-india-fssai also manage their own unique, localized permissible limits for functional additives, creating a heavily fragmented global compliance landscape [9].

Suggested Additional Sources

To further build upon this research, future queries should investigate:

1. Specific Banned Botanicals: Comprehensive lists of adaptogens outright banned by the european-commission-ec or specific EU member states (e.g., Ashwagandha bans in specific Nordic countries).
2. FDA Enforcement on Adaptogen-Infused Alcohol: Investigating whether the Alcohol and Tobacco Tax and Trade Bureau (TTB) and FDA have targeted “functional alcohol” brands attempting to blend adaptogens with ethanol.
3. State-Level Enforcement: Actions taken by State Attorneys General under consumer protection laws, particularly Prop 65 enforcement actions against heavy metals in botanical ingredients [2].

References

1. Adaptogens & FDA/FTC Compliance - Cohen Healthcare Law Group — cohenhealthcarelaw.com
2. [PDF] Legal Framework for Adaptogens, Nootropics & Botanicals — acc.com
3. FDA sends warning letters to brands selling CBD-containing foods and beverages | Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends — nutritionaloutlook.com
4. FDA Warns Illegally Selling Food & Beverage Products that Contain … — fda.gov
5. FDA Sends Warning Letters for Supplements Claiming to Treat … — fda.gov
6. Ultimate Guide to EFSA Novel Food Regulations - impossibrew — impossibrew.co.uk
7. [PDF] Functional drinks - Steptoe — steptoe.com
8. Trends and current food safety regulations and policies for functional foods and beverages containing botanicals - PMC — pmc.ncbi.nlm.nih.gov
9. FOS Limits in Functional Beverages: India, USA & EU (2025) — foodresearchlab.com
10. Novel food | EFSA — efsa.europa.eu
11. FTC and FDA Issue Warning Letters to Supplements Companies | All About Advertising Law — allaboutadvertisinglaw.com
12. Class Action Challenges Advertising Claims for Pure Nootropics’ Supplements — classaction.org
13. Checklist for Nootropic Beverage Compliance — impossibrew.co.uk
14. FTC Approves Final Order Settling Charges that “BrainStrong Adult” Supplement Marketers Made Deceptive Memory Improvement Claims | Federal Trade Commission — ftc.gov
15. Health Products Compliance Guidance - Federal Trade Commission — ftc.gov